Send to

Choose Destination
Nat Rev Cancer. 2014 Mar;14(3):187-98. doi: 10.1038/nrc3678.

Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.

Author information

Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), University of Oslo and Oslo University Hospitals, N-0318 Oslo, Norway;Departments of Cancer Prevention and Urology, Institute of Cancer Research and Oslo University Hospitals, N-0424 Oslo, Norway;Uro-Oncology Research Group, Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.

Erratum in

  • Nat Rev Cancer. 2014 May;14(5). doi: 10.1038/nrc3722.


Prostate cancer treatment is dominated by strategies to control androgen receptor (AR) activity. AR has an impact on prostate cancer development through the regulation of not only transcription networks but also genomic stability and DNA repair, as manifest in the emergence of gene fusions. Whole-genome maps of AR binding sites and transcript profiling have shown changes in the recruitment and regulatory effect of AR on transcription as prostate cancer progresses. Defining other factors that are involved in this reprogramming of AR function gives various opportunities for cancer detection and therapeutic intervention.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center